[go: up one dir, main page]

WO2023111544A3 - Benzoate salt of 5-methoxy-n,n-dimethyltryptamine - Google Patents

Benzoate salt of 5-methoxy-n,n-dimethyltryptamine Download PDF

Info

Publication number
WO2023111544A3
WO2023111544A3 PCT/GB2022/053208 GB2022053208W WO2023111544A3 WO 2023111544 A3 WO2023111544 A3 WO 2023111544A3 GB 2022053208 W GB2022053208 W GB 2022053208W WO 2023111544 A3 WO2023111544 A3 WO 2023111544A3
Authority
WO
WIPO (PCT)
Prior art keywords
dimethyltryptamine
methoxy
benzoate salt
salt
dmt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2022/053208
Other languages
French (fr)
Other versions
WO2023111544A2 (en
Inventor
Cosmo FEILDING-MELLEN
Jason Gray
Timothy Mason
Cosima Agnes RUDD GRETTON
Frank Wiegand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beckley Psytech Ltd
Original Assignee
Beckley Psytech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2118007.0A external-priority patent/GB202118007D0/en
Priority claimed from GBGB2118005.4A external-priority patent/GB202118005D0/en
Priority claimed from GBGB2118011.2A external-priority patent/GB202118011D0/en
Priority claimed from GBGB2118008.8A external-priority patent/GB202118008D0/en
Priority claimed from GBGB2118006.2A external-priority patent/GB202118006D0/en
Priority claimed from GBGB2118099.7A external-priority patent/GB202118099D0/en
Priority claimed from GBGB2118095.5A external-priority patent/GB202118095D0/en
Priority claimed from GBGB2118156.5A external-priority patent/GB202118156D0/en
Priority claimed from GBGB2212113.1A external-priority patent/GB202212113D0/en
Priority claimed from GBGB2212117.2A external-priority patent/GB202212117D0/en
Priority to EP22830588.4A priority Critical patent/EP4448488A2/en
Priority to AU2022413759A priority patent/AU2022413759A1/en
Priority to CA3242602A priority patent/CA3242602A1/en
Application filed by Beckley Psytech Ltd filed Critical Beckley Psytech Ltd
Publication of WO2023111544A2 publication Critical patent/WO2023111544A2/en
Publication of WO2023111544A3 publication Critical patent/WO2023111544A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A method of synthesizing the benzoate salt of 5-MeO-DMT comprising the step of treating the hydrochloride salt of 5-MeO-DMT with a base, prior to the addition of benzoic acid.
PCT/GB2022/053208 2021-12-13 2022-12-13 Benzoate salt of 5-methoxy-n,n-dimethyltryptamine Ceased WO2023111544A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA3242602A CA3242602A1 (en) 2021-12-13 2022-12-13 Benzoate salt of 5-methoxy-n,n-dimethyltryptamine
AU2022413759A AU2022413759A1 (en) 2021-12-13 2022-12-13 Benzoate salt of 5-methoxy-n,n-dimethyltryptamine
EP22830588.4A EP4448488A2 (en) 2021-12-13 2022-12-13 Benzoate salt of 5-methoxy-n,n-dimethyltryptamine

Applications Claiming Priority (28)

Application Number Priority Date Filing Date Title
GB2118011.2 2021-12-13
GBGB2118007.0A GB202118007D0 (en) 2021-12-13 2021-12-13 Methods of treatment
GB2118006.2 2021-12-13
GBGB2118006.2A GB202118006D0 (en) 2021-12-13 2021-12-13 Methods of treatment
GBGB2118008.8A GB202118008D0 (en) 2021-12-13 2021-12-13 Combination Pharmaceutical composition
GB2118008.8 2021-12-13
GB2118005.4 2021-12-13
GB2118007.0 2021-12-13
GBGB2118011.2A GB202118011D0 (en) 2021-12-13 2021-12-13 Methods of treatment
GBGB2118005.4A GB202118005D0 (en) 2021-12-13 2021-12-13 Methods of synthesis
GB2118099.7 2021-12-14
GBGB2118095.5A GB202118095D0 (en) 2021-12-14 2021-12-14 Combination pharmaceutical composition
GBGB2118099.7A GB202118099D0 (en) 2021-12-14 2021-12-14 Methods of synthesis
GB2118095.5 2021-12-14
GB2118156.5 2021-12-15
GBGB2118156.5A GB202118156D0 (en) 2021-12-15 2021-12-15 Methods of synthesis
GB202118305 2021-12-16
GB2118293.6 2021-12-16
GB202118293 2021-12-16
GB2118295.1 2021-12-16
GB2118309.0 2021-12-16
GB2118305.8 2021-12-16
GB202118295 2021-12-16
GB202118309 2021-12-16
GB2212113.1 2022-08-19
GBGB2212113.1A GB202212113D0 (en) 2022-08-19 2022-08-19 Method of synthesis
GBGB2212117.2A GB202212117D0 (en) 2022-08-19 2022-08-19 Method of synthesis
GB2212117.2 2022-08-19

Publications (2)

Publication Number Publication Date
WO2023111544A2 WO2023111544A2 (en) 2023-06-22
WO2023111544A3 true WO2023111544A3 (en) 2023-07-20

Family

ID=84627509

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2022/053208 Ceased WO2023111544A2 (en) 2021-12-13 2022-12-13 Benzoate salt of 5-methoxy-n,n-dimethyltryptamine

Country Status (4)

Country Link
EP (1) EP4448488A2 (en)
AU (1) AU2022413759A1 (en)
CA (1) CA3242602A1 (en)
WO (1) WO2023111544A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL297861A (en) 2020-05-08 2023-01-01 Psilera Inc New compositions of pharmaceutical substances and preparations
MX2023013928A (en) 2021-05-25 2023-12-08 Atai Therapeutics Inc NEW SALTS AND CRYSTALLINE FORMS OF N,N-DIMETHYLTRYPTAMINE SALTS.
EP4499074A1 (en) * 2022-03-27 2025-02-05 GH Research Ireland Limited 5-meo-dtm for the treatment of bipolar disorder
US12264131B2 (en) * 2022-08-19 2025-04-01 Beckley Psytech Limited Pharmaceutically acceptable salts and compositions thereof
EP4618946A1 (en) * 2022-11-14 2025-09-24 Beckley Psytech Limited Formulations of 5-meo-dmt
US12246005B2 (en) 2023-06-13 2025-03-11 Beckley Psytech Limited 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations
WO2025054397A1 (en) * 2023-09-08 2025-03-13 Atai Therapeutics, Inc. Parenteral formulations for n,n-dimethyltryptamine (dmt) and dmt analogs, methods of making, and methods of use thereof
WO2025076151A1 (en) * 2023-10-02 2025-04-10 Atai Therapeutics, Inc. N-n-dimethyltryptamine (dmt) and dmt analog oral transmucosal film compositions, methods of making, and methods of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019081764A1 (en) * 2017-10-26 2019-05-02 Consejo Superior De Investigaciones Científicas (Csic) Combination product for the treatment of neurological and/or psychiatric disorders
WO2020169851A1 (en) * 2019-02-22 2020-08-27 Gh Research Limited Compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for use in treating mental disorders
WO2021222885A1 (en) * 2020-05-01 2021-11-04 Zosano Pharma Corporation Transdermal drug delivery devices having psilocybin, lysergic acid diethylamide or 3,4-methylenedioxymethamphetamine coated microprotrusions
WO2021250435A1 (en) * 2020-06-12 2021-12-16 Beckley Psytech Limited Pharmaceutical composition comprising 5-methoxy-n,n-dimethyltryptamine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019081764A1 (en) * 2017-10-26 2019-05-02 Consejo Superior De Investigaciones Científicas (Csic) Combination product for the treatment of neurological and/or psychiatric disorders
WO2020169851A1 (en) * 2019-02-22 2020-08-27 Gh Research Limited Compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for use in treating mental disorders
WO2021222885A1 (en) * 2020-05-01 2021-11-04 Zosano Pharma Corporation Transdermal drug delivery devices having psilocybin, lysergic acid diethylamide or 3,4-methylenedioxymethamphetamine coated microprotrusions
WO2021250435A1 (en) * 2020-06-12 2021-12-16 Beckley Psytech Limited Pharmaceutical composition comprising 5-methoxy-n,n-dimethyltryptamine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FALKENBERG G., CARLSTRÖM D.: "The crystal and molecular structure of 5-methoxy-(N,N)-dimethyltryptamine hydrochloride", ACTA CRYSTALLOGRAPHICA. SECTION B, STRUCTURAL CRYSTALLOGRAPHY AND CRYSTAL CHEMISTRY., MUNKSGAARD, COPENHAGEN., DK, vol. 27, no. 2, 15 February 1971 (1971-02-15), DK, pages 411 - 418, XP009529821, DOI: 10.1107/S0567740871002309 *

Also Published As

Publication number Publication date
EP4448488A2 (en) 2024-10-23
WO2023111544A2 (en) 2023-06-22
CA3242602A1 (en) 2023-06-22
AU2022413759A1 (en) 2024-06-27

Similar Documents

Publication Publication Date Title
WO2023111544A3 (en) Benzoate salt of 5-methoxy-n,n-dimethyltryptamine
MX2022001421A (en) Tetracyclic compound, preparation method therefor and use thereof.
EP4595962A3 (en) Pharmaceutical composition
PH12023550018A1 (en) Phthalazinone compound, and preparation method therefor and medical use thereof
MX2023003778A (en) Antitumor compound, and preparation method therefor and use thereof.
MX2020005956A (en) Organic sulfonic acid salts of amino acid esters and process for their preparation.
EA202193015A1 (en) CDK INHIBITORS
CY1118189T1 (en) ENLARGEMENT OF SALT WATER AND GLUT WATER BY ADMINISTRATION OF A SOIL CALCIUM SOLUTION IN SOFT WATER
AU2017246458A1 (en) Cell-free production of ribonucleic acid
TN2012000543A1 (en) Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application
UA110983C2 (en) 1,2,3,4-TETRAHYDROCHINOLINE DERIVATIVE SUITABLE FOR THE TREATMENT OF DIABETES
EA201890899A1 (en) PHARNESIDE X-RECEPTOR MODULATORS
MX2023009037A (en) Pyrimidopyran compound.
EA201290416A1 (en) NEW SPYROPYPERIDINE CONNECTIONS
MX342746B (en) Nitrogen mustard derivatives.
MX2019004845A (en) Cylodextrin complexation methods for formulating peptide proteasome inhibitors.
MY200061A (en) Irak inhibitor and preparation method therefor and use thereof
WO2020154499A8 (en) Sulfonimidamide compounds and compositions for treating conditions associated with nlrp activity
ZA201805790B (en) Improved process for the preparation of osimertinib (azd9291) or a salt thereof, and "azd9291 aniline" or a salt thereof
MX2016004265A (en) Enzalutamide in combination with afuresertib for the treatment of cancer.
CO6341557A2 (en) NITROGEN DERIVATIVES OF PANCRATISTATINE
PH12019550154B1 (en) Azetidine derivative
EP4549450A3 (en) Solution phase synthesis and crystallization of beta-turn peptidomimetic cyclic salts
EP4174185A4 (en) Methods for preparing pantoic acid, pantothenic acid and panthenol as well as salts thereof
EA201300719A3 (en) METHOD OF ENZYMATIVE SYNTHESIS (7S) -1- (3,4-DIMETOXYBICYCLO [4.2.0] OCTA-1,3,5-TRIEN-7-IL) N-METHYLMETHANAMINE AND APPLICATION IN THE SYNTHESIS OF IVABRADINE AND ITS SALTS

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22830588

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2022413759

Country of ref document: AU

Ref document number: 811798

Country of ref document: NZ

Ref document number: AU2022413759

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 3242602

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2022413759

Country of ref document: AU

Date of ref document: 20221213

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2022830588

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2022830588

Country of ref document: EP

Effective date: 20240715